Biopharmaceutical firm Ardelyx's Q2 revenue rises 33%

Ardelyx

04/08/2025 21:14

Overview

Ardelyx Q2 2025 revenue grows 33% yr/yr to $97.7 mln

Co raises 2025 IBSRELA sales forecast to $250-$260 mln

Ardelyx ends Q2 with $238.5 mln in cash and investments

Outlook

Company raises 2025 IBSRELA net sales revenue expectations to $250-$260 mln

Ardelyx confident in XPHOZAH growth for remainder of 2025

Result Drivers

IBSRELA SALES GROWTH - IBSRELA net sales increased 84% yr/yr and 46% qtr/qtr, driven by strategic commercial execution and high demand

XPHOZAH DEMAND - XPHOZAH net sales revenue increased 27% qtr/qtr, driven by growing demand among healthcare providers

REVENUE INCREASE - Total revenue grew 33% yr/yr, attributed to increased IBSRELA and XPHOZAH sales

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Sales
$90.08 mln
Q2 EPS
-$0.08
Q2 Net Income
-$19.08 mln
Q2 Operating Expenses
$99.65 mln
Q2 Operating Income
-$14.40 mln


Press Release: ID:nGNX3rjB7b

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)